How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?

Since its first approval in 2006, 1 year of adjuvant trastuzumab has been the standard of care for early-stage HER2-positive breast cancer. Nevertheless, the optimal duration of adjuvant trastuzumab was uncertain, and the standard 12-month duration has been questioned by a number of different trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Morganti, S., Bianchini, G., Giordano, A., Giuliano, M., Curigliano, G., Criscitiello, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908056/
https://www.ncbi.nlm.nih.gov/pubmed/35272131
http://dx.doi.org/10.1016/j.esmoop.2022.100428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908056/
https://www.ncbi.nlm.nih.gov/pubmed/35272131
http://dx.doi.org/10.1016/j.esmoop.2022.100428

Ejemplares similares